NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the topic.
- Other notable experts such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Naval G. Daver, MD, also contribute to the discussion.
No specific quotes are provided in the given text.
Author's summary: NGS improves biomarker testing in solid tumors.
More News
- Flyers send Jett Luchanko back to juniors as development takes priority | NorthPennNow
- Tonight’s ‘Sports Equinox’ will showcase games throughout the NFL, MLB, NBA and NHL
- Be ready for pea-sized hail with thunderstorms in Central West Florida Monday – gusts may reach 40 mph
- The 2026 Legislative Season: Why Your Team Needs To Start Training Camp Now | JD Supra
- President Milei says he will seek consensus for new reform push
- Importing beef is not the solution | GABEL
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- First Duel Night Abyss Figure Is Based on Psyche
- Queer Issues are Human Issues - The McGill Daily
- SJHN Daily: Celebrini Named NHL First Star of the Week